Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,034.03 +15.64 (+0.31%) Dow
38,059.13 +155.84 (+0.41%) Nasdaq
15,697.15 +91.67 (+0.59%) Bitcoin USD
59,076.09 +1,667.26 (+2.90%) CMC Crypto 200
1,274.43 +3.69 (+0.29%)
AZN Jan 2025 75.000 call
| Previous close | 7.10 |
| Open | 7.35 |
| Bid | 7.05 |
| Ask | 7.20 |
| Strike | 75.00 |
| Expiry date | 2025-01-17 |
| Day's range | 7.25 - 7.35 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.89k |
Business WireCALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
WILMINGTON, Del., May 02, 2024--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL).
Business WireAstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
WILMINGTON, Del., May 01, 2024--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA from May 17 - 22, 2024. The company will present 59 abstracts, including 12 late-breaking posters, with a focus on unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA), as
Insider MonkeyAstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript
AstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript April 25, 2024 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.03 EPS, expectations were $1.22. AstraZeneca PLC isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning to those joining […]
